Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kamilla Woznica Miskowiak
Does Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence: Study Protocol of a Randomised, Double-Blinded, Placebo-Controlled Clinical Trial
BMJ Open
Medicine
Related publications
Glucagon-Like Peptide-1 Receptor (GLP1R; GLP-1R)
Science-Business eXchange
Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Double-Blind, Randomized Placebo-Controlled Clinical Trial of Benfotiamine for Severe Alcohol Dependence
Drug and Alcohol Dependence
Psychiatry
Toxicology
Mental Health
Pharmacology
The Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exendin-4 Reduces Cocaine Self-Administration in Mice
Physiology and Behavior
Philosophy
Behavioral Neuroscience
Experimental
Cognitive Psychology
A Mechanism for Agonist Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor Through Modelling & Molecular Dynamics
Biochemical and Biophysical Research Communications
Biochemistry
Cell Biology
Molecular Biology
Biophysics
Glucagon-Like Peptide-1 Receptor (GLP-1R) Signaling Ameliorates Dysfunctional Immunity in COPD Patients
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
Dose-Dependent Effects of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized, Double-Blind, Placebo-Controlled Trial
Diabetic Medicine
Internal Medicine
Endocrinology
Metabolism
Diabetes
Effects of Subcutaneous Glucagon-Like Peptide 1 (GLP-1 [7-36 Amide]) in Patients With NIDDM
Diabetologia
Internal Medicine
Endocrinology
Metabolism
Diabetes
Protocol for Meal-Time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C Trial): A Randomised, Double-Blinded, Placebo-Controlled Trial
BMJ Open
Medicine
